Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Anthony L. Cunningham; Himal Lal; Martina Kovac; Roman Chlíbek; Shinn‐Jang Hwang; Javier Díez‐Domingo; Olivier Godeaux; Myron J. Levin; Janet E. McElhaney; Joan Puig‐Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; José Fernando Barba‐Gómez; Laura Cámpora; Ferdinandus de Looze; H. Jackson Downey; Wayne Ghesquière; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Yin Weckx; W W Yeo; Thomas C. Heineman

doi:10.1056/nejmoa1603800

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cunningham et al. (2016) studied this question.

synapsesocial.com/papers/69e001ba93e101b251e9c5a4 https://doi.org/10.1056/nejmoa1603800

View Full Paper

Ask AI

Bookmark

Share

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Ask about this paper

Abstract

Discussion

Cite This Study

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading